» Articles » PMID: 11160846

Soluble HLA-G Influences the Release of Cytokines from Allogeneic Peripheral Blood Mononuclear Cells in Culture

Overview
Journal Mol Hum Reprod
Date 2001 Feb 13
PMID 11160846
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Exquisitely regulated cytokine balance during early pregnancy is thought to be necessary for promoting survival of the fetal allograft. Our previous studies have demonstrated that membrane-bound human leukocyte antigen (mHLA-G) expressed on trophoblasts is one of the key factors in regulating cytokine balance by shifting the Th1/Th2 balance toward Th2 polarization, a favourable milieu for the maintenance of pregnancy. Given that trophoblasts secrete soluble HLA-G (sHLA-G), we examined its biological roles in comparison with mHLA-G. We cultured peripheral blood mononuclear cells (PBMC) with either the HLA-A and -B-deficient B lymphoblast cell line (721.221 cells) or the same cell line transfected with mHLA-G (721.221-G1 cells), in the presence or absence of recombinant sHLA-G. Cytokine concentrations in the culture media were determined by enzyme-linked immunosorbent assay. In contrast to mHLA-G protein, sHLA-G stimulated the release of tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma, whereas it reduced the release of interleukin (IL)-3, regardless of the presence of the presence of a stimulatory effect of the mHLA-G-expressing cells. Although mHLA-G reduced the release of IL-4, sHLA-G did not have any effect. Conversely, sHLA-G stimulated the release of IL-10 whereas mHLA-G was without effect. These results suggest that sHLA-G regulates the release of cytokines from PBMC chiefly by counterbalancing mHLA-G, and thereby may play a role in maintaining pregnancy.

Citing Articles

Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success.

Rodriguez G, Yakubovich E, Vanderhyden B Cancers (Basel). 2023; 15(23).

PMID: 38067396 PMC: 10705691. DOI: 10.3390/cancers15235694.


Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis.

Amoriello R, Rizzo R, Mariottini A, Bortolotti D, Gentili V, Bonechi E Front Neurol. 2022; 13:872396.

PMID: 35693002 PMC: 9174986. DOI: 10.3389/fneur.2022.872396.


HLA-G in Allergy: Does It Play an Immunoregulatory Role?.

Negrini S, Contini P, Murdaca G, Puppo F Front Immunol. 2022; 12:789684.

PMID: 35082780 PMC: 8784385. DOI: 10.3389/fimmu.2021.789684.


Cytokines and Soluble HLA-G Levels in the Acute and Recovery Phases of Arbovirus-Infected Brazilian Patients Exhibiting Neurological Complications.

Almeida R, Brito Ferreira M, Sonon P, Cordeiro M, Sadissou I, Diniz G Front Immunol. 2021; 12:582935.

PMID: 33776990 PMC: 7994272. DOI: 10.3389/fimmu.2021.582935.


Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC.

Wu C, Caumartin J, Amodio G, Anna F, Loustau M, Gregori S Front Immunol. 2021; 11:608614.

PMID: 33505397 PMC: 7832389. DOI: 10.3389/fimmu.2020.608614.